| scholarly article | Q13442814 |
| P356 | DOI | 10.3109/07853890.2014.935470 |
| P698 | PubMed publication ID | 25058176 |
| P50 | author | Françoise Van Bambeke | Q37828419 |
| P2860 | cites work | 10 x '20 Progress--development of new drugs active against gram-negative bacilli: an update from the Infectious Diseases Society of America | Q24601746 |
| Molecular Characterization of Off-Target Activities of Telithromycin: a Potential Role for Nicotinic Acetylcholine Receptors | Q24606169 | ||
| JNJ-Q2, a new fluoroquinolone with potent in vitro activity against Staphylococcus aureus, including methicillin- and fluoroquinolone-resistant strains | Q24606219 | ||
| Binding and action of CEM-101, a new fluoroketolide antibiotic that inhibits protein synthesis | Q24606228 | ||
| Oritavancin disrupts membrane integrity of Staphylococcus aureus and vancomycin-resistant enterococci to effect rapid bacterial killing | Q24606291 | ||
| In vitro antibacterial activities of JNJ-Q2, a new broad-spectrum fluoroquinolone | Q24629223 | ||
| In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms | Q24653865 | ||
| Susceptibility rates in Latin American nations: report from a regional resistance surveillance program (2011). | Q43661807 | ||
| Pharmacodynamic profiling of modithromycin: assessment in a pneumococcal murine pneumonia model | Q44056910 | ||
| Increase in fluoroquinolone non-susceptibility among clinical Streptococcus pyogenes in Belgium during 2007-10. | Q44297287 | ||
| Analysis on distribution and genomic diversity of high-level antiseptic resistance genes qacA and qacB in human clinical isolates of Staphylococcus aureus | Q44487335 | ||
| Susceptibility of 170 isolates of the USA300 clone of MRSA to macrolides, clindamycin and the novel ketolide cethromycin | Q44669932 | ||
| Emergence of high-level azithromycin resistance in Neisseria gonorrhoeae in England and Wales. | Q45997443 | ||
| Fluoroquinolone-modifying enzyme: a new adaptation of a common aminoglycoside acetyltransferase | Q46862305 | ||
| Activity of oritavancin against methicillin-resistant staphylococci, vancomycin-resistant enterococci and β-haemolytic streptococci collected from western European countries in 2011. | Q47195965 | ||
| Activity of JNJ-Q2, a new fluoroquinolone, tested against contemporary pathogens isolated from patients with community-acquired bacterial pneumonia. | Q50969584 | ||
| In vivo activity of oritavancin in animal infection models and rationale for a new dosing regimen in humans. | Q51760113 | ||
| Activity of delafloxacin against methicillin-resistant Staphylococcus aureus: resistance selection and characterization. | Q54297668 | ||
| Antimicrobial susceptibility of 15,644 pathogens from Canadian hospitals: results of the CANWARD 2007-2009 study. | Q54367455 | ||
| Prevalence of antibiotic resistance in US hospitals. | Q54410496 | ||
| Summary of Pharmacokinetics and Tissue Distribution of a Broad-Spectrum Fluoroquinolone, JNJ-Q2. | Q39545653 | ||
| In vitro and in vivo antibacterial activity of modithromycin against streptococci and Haemophilus influenzae | Q39554970 | ||
| Dimerization and membrane anchors in extracellular targeting of vancomycin group antibiotics | Q39779438 | ||
| Activity of glycopeptides against vancomycin-resistant gram-positive bacteria | Q39819863 | ||
| Cellular accumulation and pharmacodynamic evaluation of the intracellular activity of CEM-101, a novel fluoroketolide, against Staphylococcus aureus, Listeria monocytogenes, and Legionella pneumophila in human THP-1 macrophages | Q39831380 | ||
| Activity of the investigational fluoroquinolone finafloxacin against ciprofloxacin-sensitive and -resistant Acinetobacter baumannii isolates | Q39895046 | ||
| Fitness cost of VanA-type vancomycin resistance in methicillin-resistant Staphylococcus aureus | Q41840194 | ||
| Comparative in vitro activities of the novel antibacterial finafloxacin against selected Gram-positive and Gram-negative bacteria tested in Mueller-Hinton broth and synthetic urine | Q41903626 | ||
| In vitro antibacterial activity of modithromycin, a novel 6,11-bridged bicyclolide, against respiratory pathogens, including macrolide-resistant Gram-positive cocci | Q42019020 | ||
| Comparative in vitro activity profile of oritavancin against recent gram-positive clinical isolates. | Q42111507 | ||
| Antipneumococcal activity of DW-224a, a new quinolone, compared to those of eight other agents | Q42112427 | ||
| Resistance surveillance program report for selected European nations (2011). | Q42232365 | ||
| Pharmacodynamics of a simulated single 1,200-milligram dose of oritavancin in an in vitro pharmacokinetic/pharmacodynamic model of methicillin-resistant staphylococcus aureus infection. | Q42530056 | ||
| A Phase 2 study of the novel fluoroquinolone JNJ-Q2 in community-acquired bacterial pneumonia | Q42678955 | ||
| Antibacterial activity of finafloxacin under different pH conditions against isogenic strains of Escherichia coli expressing combinations of defined mechanisms of fluoroquinolone resistance | Q42861089 | ||
| The in vitro evaluation of solithromycin (CEM-101) against pathogens isolated in the United States and Europe (2009) | Q42910757 | ||
| Interactions of oritavancin, a new semi-synthetic lipoglycopeptide, with lipids extracted from Staphylococcus aureus. | Q42989966 | ||
| In vitro activity of oritavancin against community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA), vancomycin-intermediate S. aureus (VISA), vancomycin-resistant S. aureus (VRSA) and daptomycin-non-susceptible S. aureus (DNSSA). | Q43088464 | ||
| DNA gyrase and topoisomerase IV are dual targets of zabofloxacin in Streptococcus pneumoniae | Q43093285 | ||
| Oritavancin kills stationary-phase and biofilm Staphylococcus aureus cells in vitro. | Q43169904 | ||
| In vitro activity of nemonoxacin (TG-873870), a novel non-fluorinated quinolone, against clinical isolates of Staphylococcus aureus, enterococci and Streptococcus pneumoniae with various resistance phenotypes in Taiwan | Q43260577 | ||
| Comparative in vitro activity of oritavancin against Staphylococcus aureus strains that are resistant, intermediate or heteroresistant to vancomycin | Q43298146 | ||
| Quinolones in 2005: an update. | Q36067593 | ||
| Characterizations of clinical isolates of clostridium difficile by toxin genotypes and by susceptibility to 12 antimicrobial agents, including fidaxomicin (OPT-80) and rifaximin: a multicenter study in Taiwan | Q36086377 | ||
| Role of mixed ion channel effects in the cardiovascular safety assessment of the novel anti-MRSA fluoroquinolone JNJ-Q2 | Q36166676 | ||
| Comparison of plasma, epithelial lining fluid, and alveolar macrophage concentrations of solithromycin (CEM-101) in healthy adult subjects | Q36276911 | ||
| Fluoroquinolones and anaerobes | Q36465462 | ||
| Cellular pharmacokinetics and pharmacodynamics of the glycopeptide antibiotic oritavancin (LY333328) in a model of J774 mouse macrophages. | Q36670964 | ||
| Pipeline of Known Chemical Classes of Antibiotics | Q36683409 | ||
| Mutant selection window hypothesis updated. | Q36728061 | ||
| New antibiotic agents in the pipeline and how they can help overcome microbial resistance | Q36845895 | ||
| White paper: recommendations on the conduct of superiority and organism-specific clinical trials of antibacterial agents for the treatment of infections caused by drug-resistant bacterial pathogens | Q36854025 | ||
| Pharmacokinetics and pharmacodynamics of nemonoxacin against Streptococcus pneumoniae in an in vitro infection model | Q36969966 | ||
| A combined pharmacodynamic quantitative and qualitative model reveals the potent activity of daptomycin and delafloxacin against Staphylococcus aureus biofilms. | Q37026608 | ||
| Randomized, double-blind, multicenter phase 2 study comparing the efficacy and safety of oral solithromycin (CEM-101) to those of oral levofloxacin in the treatment of patients with community-acquired bacterial pneumonia | Q37026706 | ||
| Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: pharmacodynamic evaluation and comparison with isogenic normal-pheno | Q37144809 | ||
| Geographic and temporal trends in antimicrobial nonsusceptibility in Streptococcus pneumoniae in the post-vaccine era in the United States | Q37187505 | ||
| Comparative in vitro susceptibilities of human mycoplasmas and ureaplasmas to a new investigational ketolide, CEM-101. | Q37190851 | ||
| In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates | Q37409945 | ||
| High prevalence of antibiotic-resistant Mycoplasma genitalium in nongonococcal urethritis: the need for routine testing and the inadequacy of current treatment options. | Q37579937 | ||
| Report of the 13th vancomycin-resistant Staphylococcus aureus isolate from the United States | Q37643540 | ||
| In vitro activity of nemonoxacin, a novel nonfluorinated quinolone antibiotic, against Chlamydia trachomatis and Chlamydia pneumoniae | Q37845251 | ||
| The in vitro activity of ABT773, a new ketolide antimicrobial agent | Q37875218 | ||
| The clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: a systematic review and meta-analysis. | Q37981103 | ||
| Resistance surveillance studies: a multifaceted problem--the fluoroquinolone example | Q37998398 | ||
| Prospects for new antibiotics: a molecule-centered perspective | Q38113689 | ||
| In vitro spectrum of activity of finafloxacin, a novel, pH-activated fluoroquinolone, under standard and acidic conditions | Q38283158 | ||
| Antibiotic activity against naive and induced Streptococcus pneumoniae biofilms in an in vitro pharmacodynamic model | Q38325843 | ||
| Comparison of pharmacokinetics between new quinolone antibiotics: the zabofloxacin hydrochloride capsule and the zabofloxacin aspartate tablet | Q38448189 | ||
| Oritavancin activity against Staphylococcus aureus causing invasive infections in U.S. and European hospitals: a 5-year international surveillance program | Q38848903 | ||
| Study of macrophage functions in murine J774 cells and human activated THP-1 cells exposed to oritavancin, a lipoglycopeptide with high cellular accumulation | Q39031976 | ||
| Pharmacodynamic evaluation of the activity of antibiotics against hemin- and menadione-dependent small-colony variants of Staphylococcus aureus in models of extracellular (broth) and intracellular (THP-1 monocytes) infections | Q39352419 | ||
| Macrophage killing of bacterial and fungal pathogens is not inhibited by intense intracellular accumulation of the lipoglycopeptide antibiotic oritavancin | Q39373932 | ||
| Activity of finafloxacin, a novel fluoroquinolone with increased activity at acid pH, towards extracellular and intracellular Staphylococcus aureus, Listeria monocytogenes and Legionella pneumophila | Q39539686 | ||
| The global spread of healthcare-associated multidrug-resistant bacteria: a perspective from Asia | Q27001437 | ||
| Safety profile of the respiratory fluoroquinolone moxifloxacin: comparison with other fluoroquinolones and other antibacterial classes | Q28243911 | ||
| Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers | Q33559026 | ||
| Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers | Q33559055 | ||
| In vitro activity of CEM-101, a new fluoroketolide antibiotic, against Chlamydia trachomatis and Chlamydia (Chlamydophila) pneumoniae | Q33676151 | ||
| Comparative in vitro activities of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, and other quinolones against clinical isolates | Q33676256 | ||
| Overexpression of patA and patB , Which Encode ABC Transporters, Is Associated with Fluoroquinolone Resistance in Clinical Isolates of Streptococcus pneumoniae | Q33715260 | ||
| Mixed-lipid storage disorder induced in macrophages and fibroblasts by oritavancin (LY333328), a new glycopeptide antibiotic with exceptional cellular accumulation | Q33770082 | ||
| In vitro activity of the new fluoroketolide solithromycin (CEM-101) against macrolide-resistant and -susceptible Mycoplasma genitalium strains | Q33797838 | ||
| In vitro activities of a new ketolide, ABT-773, against multidrug-resistant gram-positive cocci | Q33983762 | ||
| Mechanism of plasmid-mediated quinolone resistance | Q34025874 | ||
| Exploring the contribution of efflux on the resistance to fluoroquinolones in clinical isolates of Staphylococcus aureus | Q34059927 | ||
| Application of fluoroquinolone pharmacodynamics | Q34076026 | ||
| Antimicrobial characterisation of CEM-101 activity against respiratory tract pathogens, including multidrug-resistant pneumococcal serogroup 19A isolates | Q34102712 | ||
| Antimicrobial characterisation of solithromycin (CEM-101), a novel fluoroketolide: activity against staphylococci and enterococci | Q34149678 | ||
| Efficacy and safety of nemonoxacin versus levofloxacin for community-acquired pneumonia | Q34151093 | ||
| Ketolides: an emerging treatment for macrolide-resistant respiratory infections, focusing on S. pneumoniae | Q34281970 | ||
| Structures of ketolides and macrolides determine their mode of interaction with the ribosomal target site | Q34376530 | ||
| Optimisation of antimicrobial therapy using pharmacokinetic and pharmacodynamic parameters | Q34459145 | ||
| Contrasting effects of acidic pH on the extracellular and intracellular activities of the anti-gram-positive fluoroquinolones moxifloxacin and delafloxacin against Staphylococcus aureus | Q34528916 | ||
| Antimicrobial susceptibility and genetic characteristics of Neisseria gonorrhoeae isolates from Vietnam, 2011. | Q34563908 | ||
| Oritavancin: mechanism of action | Q34636725 | ||
| In vitro and in vivo antibacterial activities of DW-224a, a new fluoronaphthyridone | Q34680596 | ||
| Zabofloxacin (DW-224a) activity against Neisseria gonorrhoeae including quinolone-resistant strains | Q34795055 | ||
| Pharmacokinetics of solithromycin (CEM-101) after single or multiple oral doses and effects of food on single-dose bioavailability in healthy adult subjects | Q34932518 | ||
| Comparison of the efficacy and safety of oritavancin front-loaded dosing regimens to daily dosing: an analysis of the SIMPLIFI trial | Q35065786 | ||
| Antibiotic efflux pumps in prokaryotic cells: occurrence, impact on resistance and strategies for the future of antimicrobial therapy | Q35107933 | ||
| Human pharmacokinetics and safety profile of finafloxacin, a new fluoroquinolone antibiotic, in healthy volunteers. | Q35191364 | ||
| Glycopeptide antibiotics: from conventional molecules to new derivatives | Q35752864 | ||
| Oritavancin activity against vancomycin-susceptible and vancomycin-resistant Enterococci with molecularly characterized glycopeptide resistance genes recovered from bacteremic patients, 2009-2010 | Q35806241 | ||
| Changing trends in antimicrobial resistance and serotypes of Streptococcus pneumoniae isolates in Asian countries: an Asian Network for Surveillance of Resistant Pathogens (ANSORP) study | Q35806261 | ||
| Cethromycin versus clarithromycin for community-acquired pneumonia: comparative efficacy and safety outcomes from two double-blinded, randomized, parallel-group, multicenter, multinational noninferiority studies | Q35867451 | ||
| Glycopeptides in clinical development: pharmacological profile and clinical perspectives. | Q35879826 | ||
| In vitro activity of the new fluoroketolide solithromycin (CEM-101) against a large collection of clinical Neisseria gonorrhoeae isolates and international reference strains, including those with high-level antimicrobial resistance: potential treatm | Q35941481 | ||
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | antibiotic | Q12187 |
| quinolones | Q426549 | ||
| oritavancin | Q7102878 | ||
| P304 | page(s) | 512-529 | |
| P577 | publication date | 2014-07-24 | |
| P1433 | published in | Annals of Medicine | Q4767853 |
| P1476 | title | Renaissance of antibiotics against difficult infections: Focus on oritavancin and new ketolides and quinolones | |
| P478 | volume | 46 |
| Q26746616 | Chemical structure and pharmacokinetics of novel quinolone agents represented by avarofloxacin, delafloxacin, finafloxacin, zabofloxacin and nemonoxacin |
| Q88923191 | Delafloxacin In Vitro Broth Microdilution and Disk Diffusion Antimicrobial Susceptibility Testing Guidelines: Susceptibility Breakpoint Criteria and Quality Control Ranges for an Expanded-Spectrum Anionic Fluoroquinolone |
| Q26824268 | Delafloxacin, a non-zwitterionic fluoroquinolone in Phase III of clinical development: evaluation of its pharmacology, pharmacokinetics, pharmacodynamics and clinical efficacy |
| Q26746197 | Focus on JNJ-Q2, a novel fluoroquinolone, for the management of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections |
| Q40342746 | In Vitro Activity of Delafloxacin against Contemporary Bacterial Pathogens from the United States and Europe, 2014 |
| Q38940456 | Managing the oncologic patient with suspected pneumonia in the intensive care unit |
| Q41466009 | Modulation of the activity of moxifloxacin and solithromycin in an in vitro pharmacodynamic model of Streptococcus pneumoniae naive and induced biofilms |
| Q40948209 | New antibacterial agents on the market and in the pipeline |
| Q40111519 | New treatment options for lower respiratory tract infections |
| Q38363223 | Novel antibiotics: are we still in the pre-post-antibiotic era? |
| Q36086423 | Oritavancin for acute bacterial skin and skin structure infections |
| Q39026738 | Solithromycin: A Novel Fluoroketolide for the Treatment of Community-Acquired Bacterial Pneumonia |
| Q47119741 | Spotlight on solithromycin in the treatment of community-acquired bacterial pneumonia: design, development, and potential place in therapy |
| Q53779482 | Synthesis and biological evaluation of lipophilic teicoplanin pseudoaglycon derivatives containing a substituted triazole function. |
| Q28078130 | Targeting Antibiotic Resistance |
| Q38723961 | The role of solithromycin in the management of bacterial community-acquired pneumonia |
Search more.